2.39
Precedente Chiudi:
$2.26
Aprire:
$2.26
Volume 24 ore:
38,759
Relative Volume:
0.04
Capitalizzazione di mercato:
$3.36M
Reddito:
$502.40K
Utile/perdita netta:
$-7.91M
Rapporto P/E:
-0.2397
EPS:
-9.972
Flusso di cassa netto:
$-4.32M
1 W Prestazione:
+4.82%
1M Prestazione:
-4.40%
6M Prestazione:
-49.81%
1 anno Prestazione:
-82.68%
60 Degrees Pharmaceuticals Inc Stock (SXTP) Company Profile
Nome
60 Degrees Pharmaceuticals Inc
Settore
Industria
Telefono
202-327-5422
Indirizzo
1025 CONNECTICUT AVENUE NW, WASHINGTON
Confronta SXTP con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
SXTP
60 Degrees Pharmaceuticals Inc
|
2.39 | 3.36M | 502.40K | -7.91M | -4.32M | -9.972 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
424.99 | 128.84B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
527.78 | 65.38B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ARGX
Argen X Se Adr
|
549.65 | 39.67B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
251.15 | 33.82B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ONC
Beigene Ltd Adr
|
231.99 | 27.60B | 3.81B | -644.79M | -669.77M | -6.24 |
60 Degrees Pharmaceuticals Inc Borsa (SXTP) Ultime notizie
60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reaffirmed at Weiss Ratings - Defense World
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates - Nasdaq
60 Degrees Pharmaceuticals Announces 2024 Annual Results - ADVFN
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given “Sell (E+)” Rating at Weiss Ratings - Defense World
60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split - ADVFN
60 Degrees Pharmaceuticals (SXTP) Unveils Discrepancies in Babes - GuruFocus
Daily Progress: 60 Degrees Pharmaceuticals Inc (SXTP) Drop -15.51, Closing at 2.67 - DWinneX
60 Degrees Pharmaceuticals Inc (SXTP) Stock: A Comprehensive 52-Week Review - investchronicle.com
60 Degrees Pharmaceuticals Inc’s latest rating changes from various analysts - knoxdaily.com
How is SXTP’s stock performing after recent trades? - uspostnews.com
Shocking Gap: Survey Finds 3 Million Babesiosis Cases While CDC Reports Only 1,834Major Market Opportunity - Stock Titan
Form 8-KCurrent report - ADVFN
60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules - ADVFN
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) Short Interest Down 43.2% in March - Defense World
Deal Watch: Oak Hill Picks Up Where Roche Left Off In Angelman Syndrome - insights.citeline.com
Why 60 Degrees Pharmaceuticals, Inc. (SXTP) Went Down On Thursday? - MSN
60 Degrees Pharma's Breakthrough: New Clinical Trials Target Rising Tick-Borne Disease Crisis - Stock Titan
Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21 - Yahoo Finance
10 Stocks Fall Behind Amid Market Optimism - Insider Monkey
12 Health Care Stocks Moving In Wednesday's After-Market Session - Benzinga
60 Degrees Pharmaceuticals’ (SXTP) “Sell (E+)” Rating Reiterated at Weiss Ratings - Defense World
60 Degrees and Yale to progress tafenoquin for babesiosis - Yahoo
60 Degrees Pharmaceuticals (SXTP) Reports 2024 Financial Results - GuruFocus
60 Degrees Pharmaceuticals (SXTP) Announces 1-for-5 Reverse Stoc - GuruFocus
60 Degrees Pharma signs patent agreement with Yale for tick disease medicine development - Mugglehead Magazine
60 Degrees Pharmaceuticals signs Patient License Agreement with Yale - TipRanks
TNF Pharmaceuticals Inc: Navigating Market Fluctuations with a 0.75M Market Cap - investchronicle.com
60 Degrees Pharmaceuticals partners with Yale for drug development By Investing.com - Investing.com South Africa
Traders boost bets Fed will start cutting rates in May - Yahoo Finance
Mr. Yoshida's Brings the Heat with New Spicy Wing & Rib Sauce - Yahoo Finance
InventHelp Inventor Develops New Litter Removal Tool for Poultry Houses (JTK-236) - Yahoo Finance
Big Lots announces some stores will reopen. A Kentucky location will reopen this week - Yahoo Finance
60 Degrees Pharmaceuticals (SXTP) Stock Rallies On Tafenoquine Patent News - Stocks Telegraph
RPM International Stock Drops on DayGlo Parent's Weaker-Than-Expected Results - Yahoo
Will Assurant (AIZ) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance
Donaldson Exhibits Strong Prospects Despite Persisting Headwinds - Yahoo Finance
US trade rep says Trump tariffs are getting results, but things may be 'challenging' for awhile - Yahoo Finance
US Tariff Revenue Gains Seen as Undercut by Declining Trade - Yahoo Finance
SSL or XOM: Which Is the Better Value Stock Right Now? - Yahoo Finance
Barclays abandons DEI targets after pledging ‘unwavering’ commitment - Yahoo
RYTM Stock Rises 17% on Meeting Goals in Hypothalamic Obesity Study - Yahoo Finance
Watch live: U.S. Trade Rep. Jamieson Greer testifying before Senate Finance Committee - Yahoo
Didn't get a 2021 stimulus check? IRS is sending out $1,400 payments for missed credit - Yahoo
Trump to endorse coal for data center power in the face of grim market realities - Yahoo
60 Degrees Pharmaceuticals (SXTP) Teams with Yale for Tafenoquine Development - GuruFocus
Dow Jumps Over 1,100 Points; US Small Business Sentiment Falls In March - Benzinga
60 Degrees Pharmaceuticals Signs Patent License Deal to Develop Tafenoquine for Tick-Borne Disease Treatment - marketscreener.com
Sixty Degrees Pharmaceuticals Announces Patent License Agreement To Advance Development Of Tafenoquine - marketscreener.com
60 Degrees Pharmaceuticals: Surge or Slump Ahead? - timothysykes.com
SXTP60 degrees pharmaceuticals, Inc. Latest Stock News & Market Updates - Stock Titan
60 Degrees Pharmaceuticals partners with Yale for drug development - Investing.com
60 Degrees Pharmaceuticals Inc Azioni (SXTP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
60 Degrees Pharmaceuticals Inc Azioni (SXTP) insider trading
Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
---|---|---|---|---|---|---|---|
XU CHERYL | Director |
Dec 12 '24 |
Buy |
1.82 |
5,000 |
9,125 |
46,078 |
XU CHERYL | Director |
Dec 16 '24 |
Buy |
1.45 |
2,000 |
2,900 |
54,078 |
DOW GEOFFREY S | President and CEO |
Dec 09 '24 |
Buy |
1.27 |
35,823 |
45,563 |
94,580 |
DOW GEOFFREY S | President and CEO |
Dec 06 '24 |
Buy |
1.20 |
20,579 |
24,672 |
58,757 |
DOW GEOFFREY S | President and CEO |
Dec 05 '24 |
Buy |
1.11 |
17,549 |
19,520 |
38,178 |
DOW GEOFFREY S | President and CEO |
Nov 21 '24 |
Buy |
0.91 |
3,500 |
3,195 |
20,629 |
DOW GEOFFREY S | President and CEO |
Nov 19 '24 |
Buy |
0.90 |
2,500 |
2,248 |
16,129 |
DOW GEOFFREY S | President and CEO |
Nov 20 '24 |
Buy |
0.92 |
1,000 |
924 |
17,129 |
XU CHERYL | Director |
Aug 27 '24 |
Buy |
1.70 |
5,000 |
8,500 |
41,078 |
XU CHERYL | Director |
May 16 '24 |
Option Exercise |
0.22 |
2,000 |
446 |
228,934 |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):